2. Search Result
Search Result
Results for "

IAV

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

2

Peptides

2

Inhibitory Antibodies

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-158097
    IAV-IN-2

    		Influenza Virus Infection
    IAV-IN-2 (Compound MC-22) inhibits for Influenza A Virus (IAV) through blocking the entry of IAV into host cell via clathrin-mediated endocytosis (CME) .
    <em>IAV</em>-IN-2
  • HY-130626
    RSV/IAV-IN-1

    		RSV Influenza Virus Infection
    RSV/IAV-IN-1 (compound 14e) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-1 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-1 has the potential for the research of RSV and/or IAV infections .
    RSV/<em>IAV</em>-IN-1
  • HY-130627
    RSV/IAV-IN-2

    		RSV Influenza Virus Infection
    RSV/IAV-IN-2 (compound 14c) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-2 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-2 has the potential for the research of RSV and/or IAV infections .
    RSV/<em>IAV</em>-IN-2
  • HY-151967
    Anti-IAV agent 1

    		Influenza Virus Infection
    Anti-IAV agent 1 (Compound (R)-1a) is an orally active anti-influenza A virus (IAV) agent with IC50s of 0.03 and 0.06 μM against IAV H1N1 and Oseltamivir-resistant IAV H1N1 strains, respectively .
    Anti-<em>IAV</em> agent 1
  • HY-143494
    RSV/IAV-IN-3

    		RSV Influenza Virus Infection
    RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza A virus (IAV) with EC50 values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC50 values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC50 of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage .
    RSV/<em>IAV</em>-IN-3
  • HY-P99637
    Gedivumab

    MHAA4549A; RG7745

    		 Influenza Virus Infection
    Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies .
    Gedivumab
  • HY-149034
    Influenza A virus-IN-8

    S5

    		 Influenza Virus Infection
    Influenza A virus-IN-8 (S5) is a macrocyclic peptide with no cytotoxic. Influenza A virus-IN-8 is also a potent Influenza A Virus (IAV) inhibitor (with sufficient protease stability) with IC50s of 6.7 and 6.6 nM for H1 and H5 variants, respectively. Influenza A virus-IN-8 shows good affinitiescan to H1 variants, binds to a conserved region in the HA stem with a Kd of 1.0 nM .
    Influenza A virus-IN-8
  • HY-131179
    Influenza A virus-IN-1

    		Influenza Virus Infection
    Influenza A virus-IN-1 is a dihydropyrrolidones derivative and is a potent inhibitor against wide subtypes of influenza A virus (IAV) with IC50 values from 3.11 μM to 7.13 μM. Influenza A virus-IN-1 efficiently inhibits replication of IAV, up-regulates the expression of key antiviral cytokines IFN-β and antiviral protein MxA .
    Influenza A virus-IN-1
  • HY-N2095
    Atractylone

    Atractylon

    		 Influenza Virus Infection Inflammation/Immunology
    Atractylone (Atractylon) is a sesquiterpenoid extracted from Atractylodis Rhizoma. Atractylone (Atractylon) alleviates influenza A virus (IAV)-induced lung injury via regulating the TLR7 signaling pathway, and acts as a promising agent for IAV treatment. Atractylone (Atractylon) inhibits the degranulation of mast cell and exhibits potential for the treatment of mast cell-mediated allergic reactions .
    Atractylone
  • HY-128965
    N-Glycolylneuraminic acid

    NeuGc; GcNeu

    		 Influenza Virus Endogenous Metabolite Inflammation/Immunology
    N-Glycolylneuraminic acid is a nonhuman sialic acid molecule synthesized in pigs but not in humans. N-Glycolylneuraminic acid works as a decoy receptor of N-Glycolylneuraminic acid-binding influenza A viruses (IAVs) .
    N-Glycolylneuraminic acid
  • HY-134608
    Cobalt protoporphyrin IX

    Co-PPIX

    		 Reactive Oxygen Species Influenza Virus Infection
    Cobalt protoporphyrin IX (Co-PPIX) is a potent and specific heme oxygenase-1 (HO-1) inducer. Cobalt protoporphyrin IX exhibits broad-spectrum antiviral activities against Influenza A virus (IAV) .
    Cobalt protoporphyrin IX
  • HY-143495
    RSV-IN-3

    		RSV Influenza Virus Infection
    RSV-IN-3 (Compound 1) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-3 shows anti-RSV activity (EC50 = 32.70 μM) .
    RSV-IN-3
  • HY-143496
    RSV-IN-4

    		RSV Influenza Virus Infection
    RSV-IN-4 (Compound 2) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-4 shows anti-RSV activity (EC50 = 11.76 μM) .
    RSV-IN-4
  • HY-P1407
    Z-VRPR-FMK TFA

    VRPR

    		 MALT1 Influenza Virus Infection Cancer
    Z-VRPR-FMK (TFA) (VRPR), a tetrapeptide, is a selective and irreversible MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor. Z-VRPR-FMK (TFA) can protect against influenza A virus (IAV) infection .
    Z-VRPR-FMK TFA
  • HY-128965R
    N-Glycolylneuraminic acid (Standard)

    NeuGc (Standard); GcNeu (Standard)

    		 Influenza Virus Endogenous Metabolite Inflammation/Immunology
    N-Glycolylneuraminic acid (Standard) is the analytical standard of N-Glycolylneuraminic acid. This product is intended for research and analytical applications. N-Glycolylneuraminic acid is a nonhuman sialic acid molecule synthesized in pigs but not in humans. N-Glycolylneuraminic acid works as a decoy receptor of N-Glycolylneuraminic acid-binding influenza A viruses (IAVs) .
    N-Glycolylneuraminic acid (Standard)
  • HY-155514
    HA-IN-1

    		Influenza Virus Inflammation/Immunology
    HA-IN-1 (compound 5g) is a Hemagglutinin (HA) ligand with high affinity, targeting to the trypsin cleavage site of HA. HA-IN-1 inhibits HA-mediated membrane fusion and reduces the pulmonary virus titer in vivo. HA-IN-1 is a potential influenza A virus (IAV) inhibitor, and an anti-influenza agent .
    HA-IN-1
  • HY-163364
    DS-22-inf-021

    		Influenza Virus Infection
    DS-22-inf-021 is a neuraminidase (NA) inhibitor. DS-22-inf-021 has antiviral activity against influenza viruses .
    DS-22-inf-021
  • HY-151267
    SARS-CoV-2-IN-25

    		SARS-CoV Infection
    SARS-CoV-2-IN-25 (Compound CP026) is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC50 of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes .
    SARS-CoV-2-IN-25
  • HY-151267A
    SARS-CoV-2-IN-25 disodium

    		SARS-CoV Infection
    SARS-CoV-2-IN-25 (Compound CP026) disodium is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC50 of 1.6 μM. SARS-CoV-2-IN-25 disodium inhibits enveloped viruses and liposomes .
    SARS-CoV-2-IN-25 disodium
  • HY-P99620
    Firivumab

    CT-P22; CT120

    		 Influenza Virus Infection
    Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
    Firivumab
  • HY-100858
    PP7

    		Influenza Virus Infection
    PP7 is a potent PB1-PB2 interaction inhibitor with an IC50 of 8.6 μM, and their inhibition against viral polymerase activity (IC50=9.5 μM). PP7 shows antiviral activities against influenza A virus (IAV), including A(H1N1)pdm09 (EC50=1.4 μM), A(H7N9) and A(H9N2) subtypes .
    PP7
  • HY-151269A
    SARS-CoV-2-IN-23 disodium

    		SARS-CoV Infection
    SARS-CoV-2-IN-23 disodium is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 disodium exhibits antiviral activity with IC50s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 disodium induces liposomal membrane disruption with an EC50 value of 4.4 μM .
    SARS-CoV-2-IN-23 disodium
  • HY-151269
    SARS-CoV-2-IN-26

    		SARS-CoV Infection
    SARS-CoV-2-IN-23 is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 exhibits antiviral activity with IC50s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 induces liposomal membrane disruption with an EC50 value of 4.4 μM .
    SARS-CoV-2-IN-26
  • HY-151276
    SARS-CoV-2-IN-29

    		SARS-CoV Infection
    SARS-CoV-2-IN-29 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 exhibits antiviral activity with IC50s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 induces liposomal membrane disruption with an EC50 value of 3.0 μM .
    SARS-CoV-2-IN-29
  • HY-151278
    SARS-CoV-2-IN-30

    		SARS-CoV Infection
    SARS-CoV-2-IN-30 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 exhibits antiviral activity with IC50s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 induces liposomal membrane disruption with an EC50 value of 6.9 μM .
    SARS-CoV-2-IN-30
  • HY-151276A
    SARS-CoV-2-IN-29 disodium

    		SARS-CoV Infection
    SARS-CoV-2-IN-29 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 disodium exhibits antiviral activity with IC50s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 disodium induces liposomal membrane disruption with an EC50 value of 3.0 μM .
    SARS-CoV-2-IN-29 disodium
  • HY-151278A
    SARS-CoV-2-IN-30 disodium

    		SARS-CoV Infection
    SARS-CoV-2-IN-30 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 disodium exhibits antiviral activity with IC50s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 disodium induces liposomal membrane disruption with an EC50 value of 6.9 μM .
    SARS-CoV-2-IN-30 disodium
  • HY-151271A
    SARS-CoV-2-IN-27 disodium

    		SARS-CoV Infection
    SARS-CoV-2-IN-27 disodium is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 disodium exhibits antiviral activity with IC50s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 disodium induces liposomal membrane disruption with an EC50 value of 6.5 μM .
    SARS-CoV-2-IN-27 disodium
  • HY-151274
    SARS-CoV-2-IN-28

    		SARS-CoV Infection
    SARS-CoV-2-IN-28 is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 exhibits antiviral activity with IC50s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 induces liposomal membrane disruption with an EC50 value of 4.4 μM .
    SARS-CoV-2-IN-28
  • HY-151271
    SARS-CoV-2-IN-27

    		SARS-CoV Infection
    SARS-CoV-2-IN-27 is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 exhibits antiviral activity with IC50s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 induces liposomal membrane disruption with an EC50 value of 6.5 μM .
    SARS-CoV-2-IN-27
  • HY-151274A
    SARS-CoV-2-IN-28 disodium

    		SARS-CoV Infection
    SARS-CoV-2-IN-28 disodium is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 disodium exhibits antiviral activity with IC50s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 disodium induces liposomal membrane disruption with an EC50 value of 4.4 μM .
    SARS-CoV-2-IN-28 disodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: